Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 5c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.54), $0.05 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $893 thousand versus the consensus estimate of $390 thousand.

“Our accomplishments in 2018 position us for multiple potential clinical milestones in 2019 and 2020 that bring us closer to our vision of building a fully integrated company with medicines that provide a profound benefit for patients,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Building on promising clinical data for both our lead programs, we plan to expand our ongoing Phase 2 trial of SY-1425 in combination with azacitidine with the addition of a cohort in RARA and IRF8 biomarker-positive relapsed or refractory AML patients. We have also added a cohort of recurrent ovarian clear cell cancer patients to our ongoing Phase 1 trial of SY-1365. The unmet need in both these patient populations is significant, and we believe these cohorts could lead to rapid clinical proof-of-concept. These new cohorts, when combined with our ongoing evaluation of SY-1365 as a single agent in patients with high-grade serous ovarian cancer, give us three potential fast-to-market opportunities for our lead programs. We are focused on executing on our clinical trials with the aim of delivering much-needed therapies to patients as quickly as possible.”

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• Boeing (BA) Statement on U.S. Air Force Collaborative Combat Aircraft Announcement
• Empire State Realty Trust (ESRT) Reports Q1 EPS of $0.03